1.Bhatt S, Weiss D, Cameron E, Bisanzio D, Mappin B, Dalrymple U, Battle K, Moyes C, Henry A, Eckhoff P: The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015. Nature 2015, 526:207.
2.WHO: World malaria report 2014. Geneva: WHO; 2014. Google Scholar 2016.
3.Lindblade KA, Steinhardt L, Samuels A, Kachur SP, Slutsker L: The silent threat: asymptomatic parasitemia and malaria transmission. Expert review of anti-infective therapy 2013, 11:623–639.
4.WHO: World malaria report 2016. Geneva: World Health Organization; 2016. 2017.
5.Ndong IC, van Reenen M, Boakye DA, Mbacham WF, Grobler AF: Trends in malaria admissions at the Mbakong Health Centre of the North West Region of Cameroon: a retrospective study. Malaria Journal 2014, 13:328.
6.Brady OJ, Slater HC, Pemberton-Ross P, Wenger E, Maude RJ, Ghani AC, Penny MA, Gerardin J, White LJ, Chitnis N: Role of mass drug administration in elimination of Plasmodium falciparum malaria: a consensus modelling study. The Lancet Global Health 2017, 5:e680-e687.
7.Organization WH: Mass drug administration for falciparum malaria: a practical field manual. 2017.
8.Adhikari B, James N, Newby G, von Seidlein L, White NJ, Day NPJ, Dondorp AM, Pell C, Cheah PY: Community engagement and population coverage in mass anti-malarial administrations: a systematic literature review. Malaria Journal 2016, 15:523.
9.Crowell V, Briët OJT, Hardy D, Chitnis N, Maire N, Pasquale AD, Smith TA: Modelling the cost-effectiveness of mass screening and treatment for reducing Plasmodium falciparum malaria burden. Malaria Journal 2013, 12:4.
10.Poirot E, Skarbinski J, Sinclair D, Kachur SP, Slutsker L, Hwang J: Mass drug administration for malaria. The Cochrane database of systematic reviews 2013:1.
11.Shekalaghe SA, Drakeley C, van den Bosch S, ter Braak R, van den Bijllaardt W, Mwanziva C, Semvua S, Masokoto A, Mosha F, Teelen K, et al: A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania. Malaria Journal 2011, 10:247.
12.Song J, Socheat D, Tan B, Dara P, Deng C, Sokunthea S, Seila S, Ou F, Jian H, Li G: Rapid and effective malaria control in Cambodia through mass administration of artemisinin-piperaquine. Malaria Journal 2010, 9:57.
13.von Seidlein L, Greenwood BM: Mass administrations of antimalarial drugs. Trends in parasitology 2003, 19:452–460.
14.Okell LC, Griffin JT, Kleinschmidt I, Hollingsworth TD, Churcher TS, White MJ, Bousema T, Drakeley CJ, Ghani AC: The Potential Contribution of Mass Treatment to the Control of Plasmodium falciparum Malaria. PLOS ONE 2011, 6:e20179.
15.Organization WH: Mass drug administration, mass screening and treatment and focal screening and treatment for malaria. Geneva, World Health Organization 2015a Reference Source 2015.
16.Landier J, Parker DM, Thu AM, Lwin KM, Delmas G, Nosten FH, Andolina C, Aguas R, Ang SM, Aung EP, et al: Effect of generalised access to early diagnosis and treatment and targeted mass drug administration on Plasmodium falciparum malaria in Eastern Myanmar: an observational study of a regional elimination programme. The Lancet 2018, 391:1916–1926.
17.Von Seidlein L, Peto TJ, Landier J, Nguyen T-N, Tripura R, Phommasone K, Pongvongsa T, Lwin KM, Keereecharoen L, Kajeechiwa L: The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in Southeast Asia: a cluster randomised trial. PLoS medicine 2019, 16:e1002745.
18.Kaehler N, Adhikari B, Cheah PY, von Seidlein L, Day NP, Paris DH, Tanner M, Pell C: Prospects and strategies for malaria elimination in the Greater Mekong Sub-region: a qualitative study. Malaria Journal 2019, 18:203.
19.Kaehler N, Adhikari B, Cheah PY, Day NP, Paris DH, Tanner M, Pell C: The promise, problems and pitfalls of mass drug administration for malaria elimination: a qualitative study with scientists and policymakers. International health 2018, 11:166–176.
20.Newby G, Hwang J, Koita K, Chen I, Greenwood B, Von Seidlein L, Shanks GD, Slutsker L, Kachur SP, Wegbreit J: Review of mass drug administration for malaria and its operational challenges. The American journal of tropical medicine and hygiene 2015, 93:125–134.
21.Pell CL, Adhikari B, Thwin MM, Kajeechiwa L, Nosten S, Nosten FH, Sahan KM, Smithuis FM, Nguyen T-N, Hien TT: Community engagement, social context and coverage of mass anti-malarial administration: comparative findings from multi-site research in the greater Mekong sub-region. PloS one 2019, 14:e0214280.
22.Adhikari B, Pell C, Phommasone K, Soundala X, Kommarasy P, Pongvongsa T, Henriques G, Day NP, Mayxay M, Cheah PY: Elements of effective community engagement: lessons from a targeted malaria elimination study in Lao PDR (Laos). Global health action 2017, 10:1366136.
23.Chen I, Clarke SE, Gosling R, Hamainza B, Killeen G, Magill A, O’Meara W, Price RN, Riley EM: “Asymptomatic” malaria: a chronic and debilitating infection that should be treated. PLoS medicine 2016, 13:e1001942.
24.Koram KA, Ahorlu CK: Towards Effective Disease Control in Ghana: Research and Policy Implications: Volume 2 Other Infectious Diseases and Health Systems. Sub-Saharan Publishers; 2014.
25.Pongvongsa T, Phommasone K, Adhikari B, Henriques G, Chotivanich K, Hanboonkunupakarn B, Mukaka M, Peerawaranun P, von Seidlein L, Day NP: The dynamic of asymptomatic Plasmodium falciparum infections following mass drug administrations with dihydroarteminisin–piperaquine plus a single low dose of primaquine in Savannakhet Province, Laos. Malaria journal 2018, 17:405.
26.Dierickx S, Gryseels C, Mwesigwa J, O’Neill S, Bannister-Tyrell M, Ronse M, Jaiteh F, Gerrets R, D’Alessandro U, Grietens KP: Factors associated with non-participation and non-adherence in directly observed mass drug administration for malaria in The Gambia. PLoS One 2016, 11:e0148627.
27.Silumbwe A, Zulu JM, Halwindi H, Jacobs C, Zgambo J, Dambe R, Chola M, Chongwe G, Michelo C: A systematic review of factors that shape implementation of mass drug administration for lymphatic filariasis in sub-Saharan Africa. BMC public health 2017, 17:484.
28.Ndong IC, Okyere D, Enos JY, Amambua-Ngwa A, Merle CSC, Nyarko A, Koram KA, Ahorlu CS: Challenges and perceptions of implementing mass testing, treatment and tracking in malaria control: a qualitative study in Pakro sub-district of Ghana. BMC Public Health 2019, 19:695.
29.Cissé B, Ba EH, Sokhna C, Ndiaye JL, Gomis JF, Dial Y, Pitt C, Ndiaye M, Cairns M, Faye E, et al: Effectiveness of Seasonal Malaria Chemoprevention in Children under Ten Years of Age in Senegal: A Stepped-Wedge Cluster-Randomised Trial. PLOS Medicine 2016, 13:e1002175.
30.Ndong IC, Reenen Mv, Boakye DA, Mbacham WF, Grobler AF: Trends in malaria case management following changes in the treatment policy to artemisinin combination therapy at the Mbakong Health Centre, Cameroon 2006–2012: A retrospective study. Acta Tropica 2015, 150:100–106.
31.Bousema JT, Gouagna LC, Drakeley CJ, Meutstege AM, Okech BA, Akim IN, Beier JC, Githure JI, Sauerwein RW: Plasmodium falciparum gametocyte carriage in asymptomatic children in western Kenya. Malaria journal 2004, 3:18.
32.Greenwood B: Asymptomatic malaria infections—do they matter? Parasitology today 1987, 3:206–214.
33.Adhikari B, Phommasone K, Pongvongsa T, Koummarasy P, Soundala X, Henriques G, Sirithiranont P, Parker DM, von Seidlein L, White NJ, et al: Treatment-seeking behaviour for febrile illnesses and its implications for malaria control and elimination in Savannakhet Province, Lao PDR (Laos): a mixed method study. BMC health services research 2019, 19:252–252.
34.Mangham LJ, Cundill B, Ezeoke O, Nwala E, Uzochukwu BS, Wiseman V, Onwujekwe O: Treatment of uncomplicated malaria at public health facilities and medicine retailers in south-eastern Nigeria. Malar J 2011, 10:155.
35.Haldar K, Bhattacharjee S, Safeukui I: Drug resistance in Plasmodium. Nature Reviews Microbiology 2018, 16:156.
36.Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, Sreng S, Anderson JM, Mao S, Sam B: Spread of artemisinin resistance in Plasmodium falciparum malaria. New England Journal of Medicine 2014, 371:411–423.
37.Maiga H, Lasry E, Diarra M, Sagara I, Bamadio A, Traore A, Coumare S, Bahonan S, Sangare B, Dicko Y, et al: Seasonal Malaria Chemoprevention with Sulphadoxine-Pyrimethamine and Amodiaquine Selects Pfdhfr-dhps Quintuple Mutant Genotype in Mali. PLOS ONE 2016, 11:e0162718.
38.Owek CJ, Oluoch E, Wachira J, Estambale B, Afrane YA: Community perceptions and attitudes on malaria case management and the role of community health workers. Malaria Journal 2017, 16:272.
39.Pitt C, Ndiaye M, Conteh L, Sy O, Hadj Ba E, Cissé B, Gomis JF, Gaye O, Ndiaye J-L, Milligan PJ: Large-scale delivery of seasonal malaria chemoprevention to children under 10 in Senegal: an economic analysis. Health policy and planning 2017, 32:1256–1266.
40.Druetz T, Corneau-Tremblay N, Millogo T, Kouanda S, Ly A, Bicaba A, Haddad S: Impact Evaluation of Seasonal Malaria Chemoprevention under Routine Program Implementation: A Quasi-Experimental Study in Burkina Faso. 2017.
41.Ahorlu CK, Koram KA, Seake-Kwawu AK, Weiss MG: Two-year evaluation of Intermittent Preventive Treatment for Children (IPTc) combined with timely home treatment for malaria control in Ghana. Malaria journal 2011, 10:127.
42.Otupiri E, Yar D, Hindin J: Prevalence of Parasitaemia, Anaemia and treatment outcomes of Malaria among School Children in a Rural Community in Ghana. Journal of Science and Technology (Ghana) 2012, 32:1–10.
43.Sarpong N, Owusu-Dabo E, Kreuels B, Fobil JN, Segbaya S, Amoyaw F, Hahn A, Kruppa T, May J: Prevalence of malaria parasitaemia in school children from two districts of Ghana earmarked for indoor residual spraying: a cross-sectional study. Malaria journal 2015, 14:260.
44.NMCP: Annual Report 2015. Nationala Malaria Control Programme 2016, Ghana Health Service.
45.Agandaa SA, Kweku M, Agboli E, Takase M, Takramah W, Tarkang E, Gyapong J: Implementation and challenges of test, treat and track (T3) strategy for malaria case management in children under five years in the Bongo District, Ghana. Clin Res Trials 2016, 2:235–241.
46.Ahorlu CK, Koram KA, Seakey AK, Weiss MG: Effectiveness of combined intermittent preventive treatment for children and timely home treatment for malaria control. Malaria Journal 2009, 8:292.
47.Greenwood B, Mutabingwa T: Malaria in 2002. Nature 2002, 415:670–672.
48.Doolan DL, Dobaño C, Baird JK: Acquired immunity to malaria. Clinical microbiology reviews 2009, 22:13–36.
49.DHS: Demographic Health Survey 2014. Ghana Statistics Service 2014.
50.GSS: Population and Housing Sensors Ghana Statistics Service 2010.
51.Ansah EK, Narh-Bana S, Epokor M, Akanpigbiam S, Quartey AA, Gyapong J, Whitty CJ: Rapid testing for malaria in settings where microscopy is available and peripheral clinics where only presumptive treatment is available: a randomised controlled trial in Ghana. BMJ: British Medical Journal 2010, 340.
52.Bousema T, Okell L, Felger I, Drakeley C: Asymptomatic malaria infections: detectability, transmissibility and public health relevance. Nature reviews Microbiology 2014, 12:833.
53.O’Meara WP, Bejon P, Mwangi TW, Okiro EA, Peshu N, Snow RW, Newton CR, Marsh K: Effect of a fall in malaria transmission on morbidity and mortality in Kilifi, Kenya. The lancet 2008, 372:1555–1562.
54.Halliday KE, Okello G, Turner EL, Njagi K, Mcharo C, Kengo J, Allen E, Dubeck MM, Jukes MC, Brooker SJ: Impact of intermittent screening and treatment for malaria among school children in Kenya: a cluster randomised trial. PLoS medicine 2014, 11:e1001594.
55.Ja S, Ja B: Mwangi i, et al. relation between falciparum malaria and bacteraemia in Kenyan children: a population-based, case-control study and a longitudinal study. Lancet 2011, 378:1316–1323.